Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T cells take on stubborn leukemia after transplant in new trial

NCT ID NCT07441291

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments for patients with B-cell acute lymphoblastic leukemia who still have small amounts of cancer cells (minimal residual disease) after a stem cell transplant. One group receives a single infusion of their own genetically modified immune cells (CAR-T therapy), while the other gets standard chemotherapy plus donor immune cells. The goal is to see which approach better clears these leftover cancer cells and prevents relapse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CD19 CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a more effective way to eliminate lingering leukemia cells after a stem cell transplant, potentially reducing relapse risk.
What could go wrong
This is a relatively small, early-phase trial, and CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological problems. It may not prove superior to standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 3-\<80 years * ECOG performance status 0-2 * post-HSCT MRD positivity (≥0.1% CD19+ abnormal B cells by flow cytometry) * no hematological/extramedullary relapse * adequate organ function * negative pregnancy test (for fertile females) Exclusion Criteria: * active infections * uncontrolled graft-versus-host disease (GVHD) * history of central nervous system disorders * autoimmune diseases * other active malignancies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allogenetic hematopoietic stem cell transplantation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Neoplasm, Residual precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allogenetic hematopoietic stem cell transplantation B-ALL MRD-positive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, China, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.